Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00165269 · ClinicalTrials.gov registry record · Phase 2

Mantle Irradiation for Hodgkin's Disease

A Phase 2 study of Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target
2
Study locations

NCT00165269 is a Phase 2 study of Hodgkin's Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants, below the 233-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00165269, a Phase 2 study of Hodgkin's Disease, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.

Conditions Studied

Interventions

  • PROCEDURE Mantle irradiation

Study Locations (2)

Massachusetts

  • Dana-Farber Cancer Center - Boston
  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 1992-05
Est. Completion 2008-02
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT00165269

The ClinicalTrials.gov registry entry for NCT00165269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (57% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hodgkin's Disease appearing as the primary indexed condition, and to 1 intervention - of which Mantle irradiation is the first listed.

NCT00165269 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00165269 about?

NCT00165269 is a clinical study titled "Mantle Irradiation for Hodgkin's Disease". The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.

What is the current status of trial NCT00165269?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1992-05. Estimated completion is 2008-02.

What conditions does trial NCT00165269 study?

This clinical trial studies the following conditions: Hodgkin's Disease.

What interventions are being tested in trial NCT00165269?

The interventions under investigation include: Mantle irradiation (PROCEDURE).

Who is sponsoring clinical trial NCT00165269?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00165269 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hodgkin's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.